Scarica l'app Stockscreener
61.87
1.20%
-0.75
Dopo l'orario di chiusura:
62.00
0.13
+0.21%
Precedente Chiudi:
$62.62
Aprire:
$62.3
Volume 24 ore:
662.12K
Relative Volume:
0.47
Capitalizzazione di mercato:
$9.21B
Reddito:
-
Utile/perdita netta:
$-946.53M
Rapporto P/E:
-8.8812
EPS:
-6.9664
Flusso di cassa netto:
$-814.94M
1 W Prestazione:
+2.74%
1M Prestazione:
+13.19%
6M Prestazione:
+0.85%
1 anno Prestazione:
+91.61%
Intervallo 1D:
$61.23
$63.05
Intervallo di 1 settimana:
$59.50
$63.98
Portata 52W:
$29.87
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Nome
Vaxcyte Inc
Settore
Industria
Telefono
650-837-0111
Indirizzo
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
61.87 | 9.13B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Reiterato | Needham | Buy |
| 2025-09-12 | Iniziato | Goldman | Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Iniziato | Goldman | Buy |
| 2023-12-07 | Iniziato | Mizuho | Buy |
| 2023-04-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-03 | Reiterato | Needham | Buy |
| 2022-12-15 | Iniziato | Guggenheim | Buy |
| 2022-11-17 | Iniziato | BTIG Research | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-24 | Ripresa | Jefferies | Buy |
| 2020-07-07 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Iniziato | Needham | Buy |
Mostra tutto
Vaxcyte Inc Borsa (PCVX) Ultime notizie
If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone - AOL.com
Vaxcyte: Not Enough Safety Margin With Current Price (NASDAQ:PCVX) - Seeking Alpha
Vaxcyte (PCVX) Rallies 3.7% to $60.22 as Vaccine Pipeline Momentum BuildsBPI Bear Confirmed - vinanet.vn
PCVX Q2 2026 Earnings: Narrower-than-Expected Loss Yields 3.7% Share GainEPS Estimate Trend - vinanet.vn
Vaxcyte (PCVX) Climbs 3.14% to $59.90, Approaching Key Resistance at $62.90Breakaway Gap - vinanet.vn
Vaxcyte, Inc. (PCVX) Stock Analysis: Unraveling The 87.70% Potential Upside - DirectorsTalk Interviews
Seth Klarman Is Completely Out of Vaxcyte — Here's What's Left - Kavout | AI
Will Vaxcyte's (PCVX) Expanded Losses and Fully Enrolled VAX-31 Trials Reframe Its Risk‑Reward Narrative - simplywall.st
Odyssean, LLC's Vaxcyte Inc(PCVX) Holding History - GuruFocus
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Zacks Research - MarketBeat
(PCVX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assenagon Asset Management S.A. Decreases Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Janus Henderson Group (PCVX) discloses 18.0M-share Vaxcyte ownership stake - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Potential 87.70% Upside with Innovative Vaccine Pipeline - DirectorsTalk Interviews
Bank of America Corp DE Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte Inc (PCVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vaxcyte (NASDAQ:PCVX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Janus Henderson Group (PCVX) discloses 65,694 Vaxcyte shares held for clients - Stock Titan
Needham Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $110 - Moomoo
The Manufacturers Life Insurance Company Trims Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. $PCVX Shares Acquired by Dimensional Fund Advisors LP - marketbeat.com
Analysts Offer Insights on Healthcare Companies: Vaxcyte (PCVX), Black Diamond Therapeutics (BDTX) and Sarepta Therapeutics (SRPT) - The Globe and Mail
FMR LLC (PCVX) discloses 20.8M-share beneficial stake in Vaxcyte common stock - Stock Titan
TD Cowen Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $75 - Moomoo
PCVX SWOT Analysis: Key Financial Insights Revealed in 10-Q Fili - GuruFocus
Vaxcyte (NASDAQ:PCVX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Vaxcyte (NASDAQ:PCVX) Insider Harpreet Dhaliwal Sells 17,000 Shares - marketbeat.com
Vaxcyte (PCVX) Advances Phase 3 Trials Amid Mixed Market Signals - GuruFocus
Vaxcyte, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells 2,250 Shares of Stock - MarketBeat
Vaxcyte Q2 net loss widens on higher expenses - TradingView
Vaxcyte, Inc. Q2 2026: Net loss $(284.3M), EPS $(1.97) — 10-Q Summary - TradingView
PCVX: Phase 3 VAX-31 adult trials fully enrolled; OPUS-1 topline data expected Q4 2026 - TradingView
Vaxcyte (Nasdaq: PCVX) posts $605M YTD loss and $2.5B cash balance - Stock Titan
Vaxcyte reports $2.5B cash; Q2 net loss $284.3M, R&D up to $267.9M - TradingView
Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Vaxcyte, Inc. SEC Filing (Aug 5, 2026) - Stock Titan
BRIEF-Vaxcyte Q2 Operating Expenses USD 302.777 Million - TradingView
Press Release: Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update - Moomoo
PCVX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
PCVX (PCVX) holder plans August 3 sale after option exercise - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Unpacking The 101.55% Potential Upside - DirectorsTalk Interviews
PCVX (PCVX): insider Andrew Guggenhime plans 10,000-share stock sale - Stock Titan
Current ratio of Vaxcyte, Inc. – XETR:5VA - TradingView
DV Trading LLC Takes Position in Vaxcyte, Inc. $PCVX - MarketBeat
Liquidity Mapping Around (PCVX) Price Events - Stock Traders Daily
59,061 Shares in Vaxcyte, Inc. $PCVX Purchased by Stempoint Capital LP - MarketBeat
Vaxcyte Inc (PCVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Vaxcyte (PCVX) Projected to Release Quarterly Earnings on Wednesday - MarketBeat
Vaxcyte Inc Azioni (PCVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vaxcyte Inc Azioni (PCVX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dhaliwal Harpreet S. | Chief Technical Ops Officer |
Aug 05 '26 |
Sale |
55.00 |
17,000 |
935,068 |
76,756 |
| Wassil Jim | CHIEF OPERATING OFFICER |
Aug 03 '26 |
Option Exercise |
5.35 |
2,250 |
12,038 |
159,791 |
| Wassil Jim | CHIEF OPERATING OFFICER |
Aug 03 '26 |
Sale |
53.86 |
2,250 |
121,195 |
157,541 |
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Aug 03 '26 |
Option Exercise |
5.35 |
10,000 |
53,500 |
115,176 |
| GUGGENHIME ANDREW | PRESIDENT AND CFO |
Aug 03 '26 |
Sale |
53.89 |
10,000 |
538,879 |
105,176 |
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):